Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells

Human γδ T cells expressing Vγ9Vδ2 T cell receptors play a crucial role in the innate immune system and have an attracted interest as effector cells in adoptive cellular immunotherapy. However, the efficacy of adoptive cellular immunotherapy for the treatment of tumors requires overcoming the immuno...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2021-10, Vol.573, p.132-139
Main Authors: Tomogane, Mako, Sano, Yusuke, Shimizu, Daiki, Shimizu, Teruki, Miyashita, Masatsugu, Toda, Yuki, Hosogi, Shigekuni, Tanaka, Yoshimasa, Kimura, Shinya, Ashihara, Eishi
Format: Article
Language:English
Subjects:
PD-1
PD-L1
RNA interference
Vγ9Vδ2 T cell
γδ T cell
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human γδ T cells expressing Vγ9Vδ2 T cell receptors play a crucial role in the innate immune system and have an attracted interest as effector cells in adoptive cellular immunotherapy. However, the efficacy of adoptive cellular immunotherapy for the treatment of tumors requires overcoming the immunosuppressive microenvironment. αβ T cell inhibition in the tumor microenvironment is associated with programmed death-ligand 1 (PD-L1) expression level. Vγ9Vδ2 T cells (abbreviated as γδ T cells here) exert potent cytotoxic effects in various cancers; however, γδ T cell activity in relation to the level of PD-L1 expression in cancer cells remains unclear, and the association between the PD-1/PD-L1 axis and γδ T cell cytotoxicity needs to be investigated. In this study, PD-1 blockade did not increase the cytotoxicity of γδ T cells against PD-L1high cancer cells. However, the anti-PD-L1 monoclonal antibody (mAb) enhanced the cytotoxicity of γδ T cells against a subset of cancer cells, whereas PD-L1 knockdown did not increase the cytotoxicity of γδ T cells. We also found that the expression levels of PD-L1 were positively correlated with the changes of γδ T cells cytotoxicity induced by anti-PD-L1 mAb. These observations suggest that anti-PD-L1 mAb treatment adds ADCC activity to the cytotoxicity of γδ T cells itself against PD-L1high cancer cells. The present results suggest that ex vivo expanded γδ T cells have antitumor activity independently of PD-L1 expression and may be promising effector cells for γδ T cell immunotherapy. •PD-1 blockade by anti-PD-1 mAb did not increase the cytotoxicity of γδ T cells.•PD-L1 knockdown did not increase the cytotoxicity of γδ T cells.•γδ T cells have antitumor activity independently of PD-L1 expression.•Anti-PD-L1 mAb enhanced γδ T cell cytotoxicity against a subset of cancer cells.•Anti-PD-L1 mAb treatment adds ADCC activity to the cytotoxicity of γδ T cells.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2021.08.005